Digest Network Come funziona
Network
/
Società
Me
Non verificato

Merck & Co., Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

202 comunicati stampa

Guarda tutti i comunicati
28/04/2026
Mercato del lavoro
Industria
Baseball
Salute
Sport
Farmaceutica
Cardiologia
Biotecnologia
Merck’s Playing with Heart Program Teams Up With Professional Baseball Clubs and Baseball Legends to Help Raise Awareness About LDL-C, Called “Bad” Cholesterol, and How It May Impact the Risk of Heart Attack or Stroke
Fonte
Merck & Co., Inc.
Emittente
Business Wire
1.00
0
24/04/2026
Mercato azionario
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.
Fonte
Merck & Co., Inc.
Emittente
Business Wire
1.00
0
21/04/2026
FDA Approves Merck’s Once-Daily IDVYNSO™ (doravirine/islatravir)
Fonte
Merck & Co., Inc.
Emittente
Business Wire
1.00
0
21/04/2026
Multimedialità
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Fonte
Merck & Co., Inc.
Emittente
Business Wire
1.00
0
17/04/2026
Industria
Igiene alimentare
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Farmaceutica
Biotecnologia
European Commission Approves Merck’s ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV Season
Fonte
Merck & Co., Inc.
Emittente
Business Wire
1.00
0
13/04/2026
Mercato del lavoro
Industria
Oncologia
Salute
Sanità
Medicina - Varie
Cardiologia
Biotecnologia
Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy
Fonte
Merck & Co., Inc.
Emittente
Business Wire
1.00
0
07/04/2026
Mercato del lavoro
Mercato azionario
Industria
Biotecnologia
Salute
Scienza
Farmaceutica
Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.
Fonte
Merck & Co., Inc.
Emittente
Business Wire
1.00
0
02/04/2026
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Ottica
Biotecnologia
Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration
Fonte
Merck & Co., Inc.
Emittente
Business Wire
1.00
0
02/04/2026
Industria
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Oncologia
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens
Fonte
Merck & Co., Inc.
Emittente
Business Wire
1.00
0
01/04/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Merck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30
Fonte
Merck & Co., Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0